Zhu et al. published an interesting correspondence [1] regarding the article we published in October 2020 in Annals of Hepatology [2].
We revised our statistics using the same software: for ALT (normal <61IU / L) mean 57.3 ± 36.1 UI/L: 48.9 ± 31.5 in patients without venous thrombo embolism (VTE) event (PNOVTE) versus 91.5 ± 71.0 in patients with VTE (PVTE), p value = 0.059. The p value are the same for the other parameters: D-dimer (in our cohort, only 40 patients/46 had a D-dimer sampling): mean 2914 ± 5362 ng/l: 1779 ± 2941 in PNOVTE versus 7315 ± 9550 in PVTE p = 0.021. For NT-proBNP (39 patients of 46 had a NT-proBNP sampling: mean 2388 ± 5361 pg /mL, 2879 ± 5927 in PNOVTE versus 2735 ± 6227 in PVTE, p = 0.52. For CPK, only 20 patients/46 had a CPK sampling: mean 124 ± 83.3 UI/L, 134 ± 83.3 in PNOVTE versus 46.5 ± 19.1 in PVTE p = 0.079 (Tables 1 and 2). The univariate analysis were estimated with Mann-Whitney test. P values less than 0.05 were considered to indicate statistical significance.
Patient characteristics.
| VARIABLE | Total 46 patientsmean | 36 NO VTEmean | 10 VTEmean | P value |
|---|---|---|---|---|
| Age (years) | 67.2 ± 12.0 | 67.1 ± 12.1 | 67.6 ± 12.4 | 0.79 |
| F (n,%) M (n,%) | 24 (52%) 22 (48%) | 20 (56%) 16 (44%) | 4 (40%) 6 (60%) | 0.48 |
| AST (<37UI/L) | 50.3 ± 34.1 | 50.4 ± 34.7 | 50.1 ± 33.7 | 0.94 |
| ALT (<61UI/L) | 57.3 ± 36.1 | 48.9 ± 31.5 | 91.5 ± 71.0 | 0.059 |
| Total Biluribin (1 − 17um/L) | 9.90 ± 4.01 | 10.1 ± 4.41 | 9.40 ± 2.84 | 1 |
| D-dimer (<500 ng/mL) | 2914 ± 5362 | 1779 ± 2941 | 7315 ± 9550 | 0.021 |
| GammaGT (15 − 85 UI/L) | 136 ± 152 | 128 ± 155 | 173 ± 145 | 0.41 |
| Alkaline phosphatase (45 − 117 UI/L) | 149 ± 206 | 159 ± 230 | 114 ± 70.7 | 0.71 |
| CRP (0 − 3 mg/L) | 83.3 ± 61.8 | 69.7 ± 53.1 | 110 ± 72.8 | 0.11 |
| GF >90 ml/min) | 78.6 ± 30.0 | 78.1 ± 31.1 | 80.7 ± 26.5 | 1 |
| BMI (kg/m2) | 27.9 ± 4.14 | 27.8 ± 4.03 | 28.3 ± 4.74 | 0.72 |
| aPTT (0.86 − 1.20) | 1.09 ± 0.298 | 1.09 ± 0.236 | 1.10 ± 0.456 | 0.19 |
| NT-proBNP (<194 pg/mL) | 2388 ± 5361 | 2879 ± 5927 | 2735 ± 6227 | 0.52 |
| CPK (26 − 192 UI/L) | 124 ± 83.3 | 134 ± 83.3 | 46.5 ± 19.1 | 0.079 |
| Hemoglobin (13.5 − 16.9 g/dL) | 12.7 ± 2.05 | 12.5 ± 1.87 | 13.2 ± 2.78 | 0.23 |
| LDH (57 − 241 UI/L) | 360 ± 151 | 361 ± 159 | 356 ± 134 | 1 |
| Lymphocyes (1.26 − 3.35 × 10.9/L) | 1.28 ± 1.39 | 1.28 ± 1.57 | 1.27 ± 0.475 | 0.16 |
| Platelets (166 − 308 × 10.9/L) | 280 ± 108 | 280 ± 108 | 301 ± 87.1 | 0.36 |
| WBC (3.91 − 10.9 × 10.9/L) | 7.85 ± 4.08) | 6.83 ± 3.52 | 11.2 ± 4.15 | <0.01 |
| Prothrombin time % | 78.3 ± 13.9 | 78.3 ± 15.0) | 78.4 ± 10.7 | 0.91 |
| Home ICU Follow-up care Death | 8 (18%) 4 (11%) 3(6.5%) | 22(63%) 6(17%) 4(11%) 2(8.6%) | 7 (70%) 2(20%) 0 (0%) 1(10%) | 0.87 |
| Hypertension | 25 (54.3%) | 22(5.5%) | 3(30%) | |
| Diabetes | 7 (15.2%) | 7(19.4%) | 0(0%) | |
| Dyslipidemia | 11 (24%) | 10 (27.8%) | 1(10%) | |
| Digestive sypmtoms | 4 (8.7%) | 3 (8.3%) | 1 (10%) | |
| History/liver diseases (n,%) | 0 (0%) | 0(%) | 0(%) | |
| Smoking | 10 (21.7%) | 10 (27.8%) | 0(0%) | |
| Lymphopenia | 29 (63%) | 24(67%) | 5(50%) | |
| Active cancer | 0 (0%) | 0 (0%) | 0 (0%) | |
| History of cancer (n,%) | 3 (6.5%) | 3 (8.3%) | 0(0%) | |
| History of VTE (n,%) | 3 (6.5%) | 2(5.5%) | 1(10%) | |
| Chronic Renal Failure | 5 (8.7%) | 5 (13.9%) | 0(0%) | |
| Haemodialysis | 2(4.3%) | 2(5.6%) | 0(0%) | |
| Sleep Apnea Syndrome | 6 (13%) | 4 (11%) | 2(20%) | |
| Septicaemia | 0 (0%) | 0 (0%) | 0 (0%) |
BMI = Body mass index. CRP = C-reactive protein. LDH = Lactic aciddehydrogenase. ICU = Intensive Care Unit. NT-proBNP = N-terminal prohormone brain natriuretic peptide. aPTT = Activated partial thromblastine time. WBC = White blood cells. CPK = creatine phosphokinase.
None.
Conflict of interestThe authors have no conflict of interest to declare.
